doi: 10.3389/fendo.2023.1084986 43
These include: Persistent fatigue, cold intolerance, or constipation (suggesting hypothyroidism) Excessive thirst, increased urination, or blurred vision (indicating poor glycaemic control) Abdominal pain, nausea, or vomiting (potential pancreatitis, a rare but serious adverse effect) Right upper quadrant pain, jaundice, pale stools, or dark urine (possible gallbladder disease, which has increased risk with GLP-1 receptor agonists) [1] [2] New visual symptoms including floaters or blurred vision (potential diabetic retinopathy complications) Mood changes, particularly low mood or increased anxiety New or worsening oedema in the legs, ankles, or face Lack of expected weight loss after three to six months at therapeutic doses should also prompt discussion with your healthcare provider
K.et al (2001)
Gaikwad S, Puangmalai N, Bittar A, Montalbano M, Garcia S, McAllen S, Bhatt N, Sonawane M, Sengupta U, Kayed R (2021) Tau oligomer induced HMGB1 release contributes to cellular senescence and neuropathology linked to Alzheimers disease and frontotemporal dementia
PubMed record Chang CH, Tsai WC, Hsu YH, Pang JH
